

Vaccine Pricing: Gavi Transitioning Countries



All prices shown in this document are Unicef awarded price per dose (in USD), per product, per supplier, per calendar year, based on multi-year supply agreements. They do not represent contractual obligations between sellers and Gavi-transitioning countries and as such are not a guarantee of price. They are provided solely for the purpose of helping Gavi transitioning countries to plan and budget adequately for self-financing.

Highlights

Starting January 2018, nine countries will be in a state of accelerated transition from Gavi support to self-financing¹, and 17 countries will have transitioned out of Gavi support².

Six manufacturers have committed to continue providing countries that transition out of Gavi support with access to the same prices accessed by Gavi-supported countries, or to maintain the prices that these countries are currently paying for certain vaccines, for a period of five years or more. These prices are only available to countries procuring through UN agencies. These commitments apply to:

- DTP-HepB-Hib (pentavalent)
- pneumococcal conjugate (PCV)
- rotavirus (Rota)
- human papillomavirus (HPV)

Table 4 shows how the UNICEF multi-year supply agreement price would apply to each of the 26 Gavi-transitioning, or fully self-financing countries, based on the supplier commitments. For these countries, please note:

- One country is currently not eligible for the price commitments to PCV, because they do not meet the Advanced Market Commitment (AMC) condition of DTP3 coverage of $\geq 70\%$;
- Six countries that had not introduced rotavirus vaccine with Gavi support are not currently covered by any price commitment for rotavirus vaccine;
- Eight countries that had not introduced HPV vaccine with Gavi support are susceptible to not being covered by any price commitment if an agreement for introduction has not been made by end of 2017;
- Countries that do not procure through UNICEF are ineligible for Pfizer's price commitments to PCV, and countries that do not procure through UNICEF or PAHO are ineligible for GSK and Merck's price commitments to Rota and HPV vaccines.

This fact sheet intends to address questions that Ministry of Health and Ministry of Financing officials may have about vaccine pricing in countries that are transitioning or have transitioned out of Gavi support. These are countries that have surpassed the Gavi Gross National Income eligibility threshold and have lost or will lose Gavi financial support to purchase vaccines.

In particular, the fact sheet aims to provide information on public sector vaccine prices that can assist Gavi-transitioning countries' financial planners in establishing appropriate budgets when countries assume full self-financing of previously Gavi-supported vaccines. Importantly, this sheet can also provide crucial information to countries contemplating new vaccine introductions.

This document is one of several tools available to Gavi-transitioning countries on the V3P website. The V3P database contains vaccine price and procurement information from 144 countries in 2017, as well as information from PAHO and UNICEF. The database, as well as documents on vaccine pricing, are available on the V3P website: <http://www.who.int/immunization/v3p>

Information for Gavi-transitioning countries is also available on the Gavi website: <http://www.gavi.org/support/apply/graduating-countries/>

This document has been prepared by the Expanded Programme on Immunization (EPI) of the Department of Immunization, Vaccines and Biologicals. It is a working document. This version of the fact sheet is **up to date as of November 2017**.

For more information on this document or on vaccine price and procurement, please email V3P-project@who.int.

¹India, Lao PDR, Nicaragua, Nigeria, Papua New Guinea, Sao Tome and Principe, Solomon Islands, Uzbekistan, Vietnam.

²Angola, Armenia, Azerbaijan, Bhutan, Bolivia, Congo, Cuba, Georgia, Guyana, Honduras, Indonesia, Kiribati, Moldova, Mongolia, Sri Lanka, Timor-Leste, Ukraine.



The GAVI Framework for Transitioning Countries

The aim of the transitioning policy is to stabilise the budgetary burden of vaccine purchases in transitioning countries (see the Gavi website at: <http://www.gavi.org/about/programme-policies/eligibility-and-transition/>). Lowest possible vaccine prices are necessary for supporting countries to sustain immunization programmes and introduce new vaccines after they no longer receive Gavi financial support. In 2018, 16 countries will be in the “preparatory transition” phase³, nine in the “accelerated transition” phase⁴, and 17 in the “fully self-financing” phase⁵. In all, 26 countries are expected to have become fully self-financing by 2023.

Gavi countries in the accelerated transition and fully self-financing phases have requested WHO to provide a clearer picture of their vaccine purchase price prospects, for both the proper budgeting of ongoing vaccination programs and the introduction of new vaccines.

Manufacturer Commitments

Three vaccine manufacturers have committed to continue to sell PCV, Rota, and HPV vaccines to countries that transition out of Gavi support at the same prices accessed by Gavi-supported countries, or to maintain the prices that these countries are currently paying, for a period of five years or more. These prices are only available to countries procuring through UNICEF (for Pfizer’s PCV vaccine) and UNICEF or PAHO (for GSK’s PCV and GSK and Merck’s Rota and HPV vaccines). The product-specific price commitments announced by vaccine manufacturers are summarised in Tables 1–3. For more information, see the Gavi website at: <http://www.gavi.org/library/gavi-documents/supply-procurement/vaccine-price-commitments-from-manufacturers/>.

Manufacturers have also made commitments for Gavi-transitioning countries for pentavalent vaccines. However, as of 2017, all UNICEF suppliers of pentavalent vaccine are offering the same price to all countries buying through UNICEF⁶, irrespective of their Gavi status. Therefore, information on pentavalent prices is not covered in this fact sheet, but is available from UNICEF at: <https://www.unicef.org/supply/files/DTP-HepB-Hib.pdf>.

³Bangladesh, Cambodia, Cameroon, Cote d'Ivoire, Djibouti, Ghana, Kenya, Kyrgyzstan, Lesotho, Mauritania, Myanmar, Pakistan, Sudan, Tajikistan, Yemen, Zambia.

⁴India, Lao PDR, Nicaragua, Nigeria, Papua New Guinea, Sao Tome and Principe, Solomon Islands, Uzbekistan, Vietnam.

⁵Angola, Armenia, Azerbaijan, Bhutan, Bolivia, Congo, Cuba, Georgia, Guyana, Honduras, Indonesia, Kiribati, Moldova, Mongolia, Sri Lanka, Timor-Leste, Ukraine.

⁶Panacea does not restrict its offer to countries buying through Unicef



Pneumococcal Conjugate Vaccine

Table 1. Price commitments, for PCV, to fully self-financing Gavi countries procuring through UNICEF SD or PAHO*, and UNICEF multi-year supply agreement prices, in 2017 (prices available at: <https://www.unicef.org/supply/files/PCV.pdf>)

Manufacturer	Presentation Size (form)	Conditions of Price Commitment	UNICEF Multi-Year Supply Agreement Prices (2017)
GSK	2-dose (liq) or any future presentation	10 years price freeze for price paid in a country's final year of Gavi support.* Not valid if a country has not yet introduced PCV with Gavi-support*** or is currently using a different manufacturer's product and wishes to switch after transition. Note: self-procuring countries should contact GSK to check for eligibility.	\$3.05
Pfizer	1-dose (liq)	Until 2025 for all Gavi eligible countries, whether vaccine is introduced before or after full self-financing. Valid if a country is currently using a different manufacturer's product and wishes to switch to a Pfizer vaccine.	\$3.30
	4-dose (liq)	Until 2025 for all Gavi eligible countries, whether the vaccine is introduced before or after full self-financing. Valid if a country is currently using a different manufacturer's product and wishes to switch to a Pfizer vaccine.	\$3.05

*Through UNICEF SD for GSK or Pfizer and through PAHO for GSK

**GSK price freeze commitment is always subject to volumes of Eligible Vaccine(s) available at the time of procurement and GSK reserves the right to increase the freeze price subject to inflation.

***Only countries with DTP3 coverage levels greater than or equal to 70%, based on the latest WHO/UNICEF estimates for 2016 (published in July 2017), can apply to Gavi for access to PCV. As of October 2017, countries that have passed the eligibility threshold and have DTP3 coverage levels greater than or equal to 70% but have not yet applied for PCV vaccine support are as follows: Bhutan, Cuba, Indonesia, Sri Lanka, Timor-Leste, Vietnam. For more information, see PCV Application Guidelines Transitioning Countries, available at: <http://www.gavi.org/library/gavi-documents/guidelines-and-forms/>.

Sources:

Unicef vaccine price data, at: http://www.unicef.org/supply/index_57476.html

Gavi, Report to the Board June 2015: <http://www.gavi.org/about/governance/gavi-board/minutes/2015/10-june/minutes/07---gavi-support-for-access-to-appropriate-pricing-for-gavi-graduated-countries/>

GSK, pricing commitments, at: <http://www.gavi.org/library/gavi-documents/supply-procurement/faq-glaxosmithkline-pricing-commitments-for-countries-transitioning-out-of-gavi%E2%80%99s-financial-support/>

Pfizer, pricing commitments at: <http://www.gavi.org/library/gavi-documents/supply-procurement/faq-pfizer-pricing-commitments-for-countries-transitioning-out-of-gavi%E2%80%99s-financial-support/>

Gavi, Manufacturers' price commitments: <http://www.gavi.org/library/gavi-documents/supply-procurement/vaccine-price-commitments-from-manufacturers/>



Rotavirus Vaccine

Table 2. Price commitments, for Rota, to fully self-financing Gavi countries procuring through UNICEF SD or PAHO, and UNICEF multi-year supply agreement prices, for 2017–2021 (prices available at: <https://www.unicef.org/supply/files/Rotavaccine.pdf>)

Manufacturer	Presentation Size (form)	Conditions of Price Commitment	UNICEF Multi-Year Supply Agreement Prices (2017-2021)
GSK	1-dose (liq) and any future presentation	10 years price freeze for price paid in a country's final year of Gavi support.* <i>Not valid</i> if a country has (a) introduced a rotavirus vaccine programme under Gavi support using a different manufacturer's product and wishes to switch after transition; or (b) not yet introduced a rotavirus vaccine programme but has crossed the eligibility threshold and completed their grace year or has completely transitioned out of Gavi support. <i>Note:</i> self-procuring countries should contact GSK to check for eligibility.	€1.88
Merck	1-dose (liq)	Commitment applies through 2025 for RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) to: Gavi accelerated transition or fully self-financing countries with GNI per capita ≤ US\$3,200 in 2013 (World Bank, 2014) that wish to introduce RotaTeq or continue an existing rotavirus vaccination program. <i>Valid</i> if countries using a competitors' product, who meet Merck's eligibility criteria, elect to switch to Merck's product.	\$3.20

*GSK price freeze commitment is always subject to volumes of vaccine(s) available at the time of procurement and GSK reserves the right to increase in the freeze price subject to inflation.

Sources:

Unicef vaccine price data, at: http://www.unicef.org/supply/index_57476.html
 Gavi, Report to the Board June 2015: <http://www.gavi.org/about/governance/gavi-board/minutes/2015/10-june/minutes/07---gavi-support-for-access-to-appropriate-pricing-for-gavi-graduated-countries/>
 GSK, pricing commitments, at: <http://www.gavi.org/library/gavi-documents/supply-procurement/faq--glaxosmithkline-pricing-commitments-for-countries-transitioning-out-of-gavi%e2%80%99s-financial-support/>

Merck, pricing commitments at: <http://www.gavi.org/Library/GAVI-documents/Supply-procurement/FAQ--Merck-pricing-commitments-for-countries-transitioning-out-of-Gavi-s-financial-support/>
 Gavi, Manufacturers' price commitments: <http://www.gavi.org/library/gavi-documents/supply-procurement/vaccine-price-commitments-from-manufacturers/>



Human Papillomavirus Vaccine

Table 3. Price commitments, for HPV, to fully self-financing Gavi countries procuring through UNICEF SD or PAHO, and UNICEF multi-year supply agreement prices, in 2017 (prices available at: <https://www.unicef.org/supply/files/Rotavaccine.pdf>)

Manufacturer	Presentation Size (form)	Conditions of Price Commitment	UNICEF Multi-Year Supply Agreement Prices (2017)
GSK	2-dose (liq)	<p>10 years price freeze for price paid in a country's final year of Gavi support.*</p> <p>Not valid if a country has (a) introduced an HPV vaccine programme under Gavi support using a different manufacturer's product and wishes to switch after transition; or (b) not yet introduced an HPV vaccine programme but has crossed the eligibility threshold and completed their grace year or has completely transitioned out of Gavi support.</p> <p>Note: For countries that had not applied for Gavi support at the time of full transition, same price commitment will be made provided:</p> <ol style="list-style-type: none"> 1. Agreement is entered on or before 31 December 2017. 2. The price-freeze offer will apply for 10 years from the effective date of such agreement and will take the form of an initial 5 year contract, renewable once for an additional period of 5 years. 3. The price shall be the same as the price last offered to the Gavi Alliance at the effective date of such agreement. <p>Note: self-procuring countries should contact GSK to check for eligibility.</p>	\$4.60
Merck	1-dose (liq)	<p>Commitment applies through 2025 for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] only:</p> <p>Applies to:</p> <ol style="list-style-type: none"> 1. Gavi accelerated transition or fully self-financing countries with a GNI per capita ≤ US\$3,200 in 2013 (World Bank, 2014) that wish to introduce GARDASIL or to continue an existing HPV vaccination program. 2. Gavi accelerated transition or fully self-financing countries with a GNI per capita > US\$3,200 that meet Gavi's Exceptional Opportunity criteria in 2016, for introduction by end 2017. <p>Procurement through Unicef or PAHO beginning with HPV program initiation is required.</p> <p>Valid if countries using a competitors' product, who meet Merck's eligibility criteria, elect to switch to Merck's product.</p>	\$4.50

*GSK price freeze commitment is always subject to volumes of vaccine(s) available at the time of procurement and GSK reserves the right to increase in the freeze price subject to inflation.

Sources:

Unicef vaccine price data, at: http://www.unicef.org/supply/index_57476.html

Gavi, Report to the Board June 2015: <http://www.gavi.org/about/governance/gavi-board/minutes/2015/10-june/minutes/07---gavi-support-for-access-to-appropriate-pricing-for-gavi-graduated-countries/>

GSK, pricing commitments, at: <http://www.gavi.org/library/gavi-documents/supply-procurement/faq--glaxosmithkline-pricing-commitments-for-countries-transitioning-out-of-gavi%e2%80%99s-financial-support/>

Merck, pricing commitments at: <http://www.gavi.org/Library/GAVI-documents/Supply-procurement/FAQ--Merck-pricing-commitments-for-countries-transitioning-out-of-Gavi-s-financial-support/>

Gavi, Manufacturers' price commitments: <http://www.gavi.org/library/gavi-documents/supply-procurement/vaccine-price-commitments-from-manufacturers/>



Vaccine Prices Accessible to Fully Self-Financing Countries

For ease of reference, the current list of UNICEF multi-year supply agreement prices⁷ is shown in Table 4. Countries that are soon-to-be or currently fully self-financing should be aware that they will continue to have access to prices offered to Gavi in UNICEF tenders, under the conditions listed above. This information is provided for the convenience and benefit of Gavi-transitioning countries to help with country budgeting. Prices shown are indicative only and are not a guarantee of price. Prices for every single product and country are specific to each negotiated tender.

Table 4. UNICEF multi-year supply agreement prices, showing which accelerated transition and fully self-financing Gavi countries meet the manufacturers' conditions for access.

	Period		PCV (2017)				Rota (2017-2021)			HPV (2017)		
	1st year accelerated transition / self-financing		Intro with Gavi ^a	GSK 2-dose vial ^b	Pfizer 1-dose vial	Pfizer 4-dose vial	Intro with Gavi ^a	GSK 1-dose ^b (2-dose course)	Merck 1-dose (3-dose course)	Intro with Gavi ^a	GSK 2-dose vial ^b (bivalent)	Merck 1-dose vial (quadrivalent)
Angola	2011	2018	Y	NE	\$3.30	\$3.05	Y	€1.88	NE	N	\$4.60 ^f	\$4.50 ^d
Armenia	2011	2018	Y	NE	\$3.30	\$3.05	Y	€1.88	NE	N ^e	NE	\$4.50 ^d
Azerbaijan	2011	2018	Y	NE	\$3.30	\$3.05	N	NE	NE	N	\$4.60 ^f	\$4.50 ^d
Bhutan	2011	2016	N	\$3.05 ^c	\$3.30	\$3.05	N	NE	\$3.20	N	\$4.60 ^f	\$4.50
Bolivia	2011	2018	Y	NE	\$3.30	\$3.05	Y	€1.88	\$3.20	Y	NE	\$4.50
Congo	2011	2018	Y	NE	\$3.30	\$3.05	Y	€1.88	\$3.20	N	\$4.60 ^f	\$4.50
Cuba	2011	2017	N	\$3.05 ^c	\$3.30	\$3.05	N	NE	NE	N	\$4.60 ^f	\$4.50 ^d
Georgia	2011	2018	Y	\$3.05	\$3.30	\$3.05	Y	€1.88	NE	N ^e	NE	\$4.50 ^d
Guyana	2012	2017	Y	NE	\$3.30	\$3.05	Y	€1.88	NE	Y	NE	\$4.50
Honduras	2011	2016	Y	NE	\$3.30	\$3.05	Y	€1.88	\$3.20	Y	NE	\$4.50
India	2017	2022	Y	NE	\$3.30	\$3.05	Y	NE	\$3.20	N	\$4.60	\$4.50
Indonesia	2011	2017	N	\$3.05 ^c	\$3.30	\$3.05	N	NE	NE	N ^e	NE	\$4.50 ^d
Kiribati	2011	2017	Y	NE	\$3.30	\$3.05	N	NE	\$3.20	N	\$4.60 ^f	\$4.50
Lao PDR	2017	2022	Y	NE	\$3.30	\$3.05	N	NE	\$3.20	N ^e	\$4.60	\$4.50
Moldova	2011	2017	Y	NE	\$3.30	\$3.05	Y	€1.88	\$3.20	N ^e	NE	\$4.50
Mongolia	2011	2016	Y	NE	\$3.30	\$3.05	N	NE	NE	N	\$4.60 ^f	\$4.50 ^d
Nicaragua	2016	2021	Y	NE	\$3.30	\$3.05	Y	€1.88	\$3.20	N	\$4.60 ^f	\$4.50
Nigeria	2017	2022	Y	\$3.05	\$3.30	\$3.05	N ^e	€1.88	\$3.20	N	\$4.60	\$4.50
PNG	2016	2021	Y	NE	\$3.30	\$3.05	N	NE	\$3.20	N	\$4.60 ^f	\$4.50
Sao Tome	2018	2023	Y	NE	\$3.30	\$3.05	Y	NE	\$3.20	N ^e	\$4.60	\$4.50
Solomon Islands	2017	2022	Y	NE	\$3.30	\$3.05	N	NE	\$3.20	N ^e	NE	\$4.50
Sri Lanka	2011	2016	N	\$3.05 ^c	\$3.30	\$3.05	N	NE	NE	Y	NE	\$4.50
Timor-Leste	2013	2018	N	\$3.05 ^c	\$3.30	\$3.05	N	NE	\$3.20	N	\$4.60 ^f	\$4.50
Ukraine	2011	2016	N	NE ^g	NE ^g	NE ^g	N	NE	NE	N	\$4.60 ^f	\$4.50 ^d
Uzbekistan	2014	2021	Y	NE	\$3.30	\$3.05	Y	€1.88	\$3.20	N	\$4.60 ^f	\$4.50
Vietnam	2015	2020	N	\$3.05 ^c	\$3.30	\$3.05	N	NE	\$3.20	N	\$4.60 ^f	\$4.50

a) Y = Yes / N = No; b) or future presentation sizes; c) not eligible for the GSK price freeze, but the country still has access to the Gavi tail-price (\$3.05-3.40) under the conditions of the AMC and until it is renegotiated; d) Gavi accelerated transition and fully self-financing countries with a 2013 GNI per capita > US\$3,200 (World Bank, 2014) that meet Gavi's Exceptional Opportunity criteria in 2016, for introduction by end of 2017; e) country approved for demonstration project with Gavi; f) Requires agreement by end of 2017; g) not currently eligible under the terms of the AMC because of low DTP3 coverage.

Legend: Countries in red = fully self-financing in 2017; Dark-shaded boxes = countries that are not eligible, or at risk of not being eligible, for Unicef prices offered to Gavi supported countries, from any of the manufacturers offering a specific vaccine; NE = Not Eligible.

Sources:

Gavi, transition process at: <http://www.gavi.org/support/apply/graduating-countries/>
 Unicef, vaccine price data at: http://www.unicef.org/supply/index_57476.html
 Gavi, Report to the Board June 2015: <http://www.gavi.org/about/governance/gavi-board/minutes/2015/10-june/minutes/07---gavi-support-for-access-to-appropriate-pricing-for-gavi-graduated-countries/>

Gavi, list of countries approved for support (as of April 30, 2017) at: <http://www.gavi.org/results/countries-approved-for-support/>

Merck, pricing commitments at: <http://www.gavi.org/Library/GAVI-documents/Supply-procurement/FAQ--Merck-pricing-commitments-for-countries-transitioning-out-of-Gavi-s-financial-support/>

Gavi, Manufacturers' price commitments: <http://www.gavi.org/library/gavi-documents/supply-procurement/vaccine-price-commitments-from-manufacturers/>

⁷Only vaccine prices are shown. Additional costs, such as shipping and transportation, insurance, handling, delivery and associated device (e.g. syringes, safety boxes, etc.) costs, are not included. Countries should carefully consider all additional costs to the price of the vaccine.



Conclusion

As of 2018, most of the 26 transitioning or fully self-financing countries will be eligible to benefit from the price commitments of manufacturers. However, some countries will be ineligible for some products.

PCV – One country can neither access the GSK nor Pfizer PCV products, at the listed prices, because they do not satisfy the AMC condition for DTP3 coverage of at least 70%.

Eighteen countries are not eligible for GSK's 2-dose presentation of PCV, at the listed price, because they are already using a different manufacturer's product, or did not introduce the product with Gavi's support and do not satisfy the conditions of the AMC.

Twenty-five of the twenty-six listed countries can access the Pfizer PCV products at the listed price.

Rota – Six countries that had not introduced Rota with Gavi support are not currently covered by the price commitments for either the GSK or Merck products.

Ten countries are not eligible for the Merck product, at the listed price, because the countries' GNIs per capita exceeded \$3,200 as of 2013. However, it is possible for any of these countries to requalify for the Merck product, should their GNI per capita fall below the \$3,200 threshold.

Fifteen countries are not eligible for the GSK product, at the listed price, because they are currently using a different manufacturer's product or had not introduced the product with Gavi's support.

HPV – Eight countries⁸ that have not introduced HPV vaccine with Gavi support are susceptible to not being covered by the price commitments for the GSK and Merck products, if an agreement for introduction is not reached by the end of 2017.

Nine countries are not eligible for the GSK product, at the listed price, because they have initiated a demonstration project, or vaccine introduction, with a different manufacturer's product.

Vaccine Prices Paid by Self-Procuring Non-Gavi, Non-PAHO MICs

Since not all fully self-financing countries are willing or able to procure through UNICEF or PAHO, and some Gavi-transitioning or fully self-financing countries are not covered by the manufacturers' price commitments, a list of price ranges for PCV, Rota and HPV vaccines are reported in Table 5 for non-Gavi, non-PAHO lower middle-income countries (LMICs) and upper middle-income countries (UMICs) reporting vaccine prices to the V3P database for 2016.

Table 5. Price ranges reported to the V3P database by self-procuring non-Gavi, non-PAHO LMICs and UMICs, for 2016.

	Presentation size	Non-Gavi LMIC* (n)	Non-Gavi UMIC** (n)
PCV	1 dose	\$12.51-19.83 (4)	\$9.85-49.99 (14)
Rota	1 dose	\$3.57-7.36 (2)	\$3.34-15.76 (7)
HPV	1 dose	\$13.69 (1)	\$7.38-113.30 (9)

*GNI per capita of between \$ 1,006 and \$3,955; **GNI per capita of between \$3,956 and \$12,235
(n) = number of countries reporting price data

Source: V3P Database at: www.who.int/immunization/v3p

DISCLAIMER

Information contained in the V3P database is provided by participating countries and/or organizations procuring on behalf of countries that have agreed to share vaccine price and procurement data with V3P. Participating countries are solely responsible for the accuracy of the data provided.

The information contained in the V3P database does not in any way imply an endorsement, certification, warranty of fitness or recommendation by WHO of any company or product for any purpose, and does not imply preference over products of a similar nature that are not mentioned. WHO furthermore does not warrant that: (1) the information is complete and/or error free; and/or that (2) the products listed are of acceptable quality, have obtained regulatory approval in any country, or that their use is otherwise in accordance with the national laws and regulations of any country, including but not limited to patent laws. Inclusion of products in the database does not furthermore imply any approval by WHO of the products in question (which is the sole prerogative of national authorities). WHO will not accept any liability or responsibility whatsoever for any injury, death, loss, damage, or other prejudice of any kind that may arise as a result of, or in connection with the procurement, distribution and use of any product listed in the V3P database.

⁸Angola, Armenia, Azerbaijan, Cuba, Georgia, Indonesia, Mongolia, Ukraine